PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced the appointment of Steve Gavel as Chief Commercial Officer, effective immediately. Gavel will oversee all aspects of commercial strategy and execution for rese-cel (resecabtagene autoleucel), the company’s lead CAR T cell therapy, as Cabaletta prepares for a potential Biologics License Application (BLA) submission in myositis in 2027.
“Steve is an outstanding leader with a track record of success launching and commercializing cellular therapies,” said Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta Bio. “His extensive cell therapy experience will enhance our efforts to maximize the value of rese-cel for patients, payers, and providers. We are confident Steve’s leadership will attract a world-class team to prepare for and to execute the potential launch of rese-cel.”
Gavel brings deep commercialization experience from his tenure at Legend Biotech, where he served as Senior Vice President of Global Cell Therapy Commercial Development from 2018 to 2025. During that time, he led the launch of CARVYKTI®, a CAR T therapy for relapsed or refractory multiple myeloma, in partnership with Johnson & Johnson. His earlier career includes senior commercial roles at Celgene (now Bristol Myers Squibb), Takeda Pharmaceuticals, Johnson & Johnson, and Immunex.
“I am honored to join the team at Cabaletta as the Company moves into the next phase of growth with an enhanced focus on commercial planning, development and execution,” Gavel said. “With a planned first BLA submission for myositis in 2027, I look forward to drawing on my previous experience with successful CAR T launches building robust commercial foundations and teams that can scale quickly with success and provide enduring value to all stakeholders in my role.”
As part of his appointment, Gavel received an inducement grant under Cabaletta’s 2025 Inducement Plan, consisting of stock options to purchase 275,000 shares of the company’s common stock at an exercise price of $2.49 per share. The options vest over four years and are subject to standard terms and conditions.
Cabaletta Bio, headquartered in Philadelphia, is a clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases, including systemic lupus erythematosus and myositis.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.